Fate therapeutics announces updated clinical data for ft819 off-the-shelf car t-cell product candidate demonstrating durability of drug-free remission for severe lupus nephritis at eular 2025 congress

All three patients treated with ft819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve primary efficacy renal response (perr); first patient to reach 1-year follow-up continues in drug-free definition of remission in sle (doris)

CAR Ratings Summary

CAR Quant Ranking